Biogen (NASDAQ:BIIB) Full Year 2023 Results

Key Financial Results

• Revenue: US$9.84b (down 3.3% from FY 2022).
• Net income: US$1.16b (down 62% from FY 2022).
• Profit margin: 12% (down from 30% in FY 2022). The decrease in margin was primarily driven by higher expenses.
• EPS: US$8.02 (down from US$20.97 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biogen EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.8% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Biogen, and understanding this should be part of your investment process.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.